Validity and Reliability of the Behavioral Regulation in Exercise Questionnaire-2 (BREQ-2) in Adolescents With Idiopathic Scoliosis

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age10-19
SponsorNigde Omer Halisdemir University

About this trial

Adolescent idiopathic scoliosis (AIS) is a spinal condition that develops during adolescence and often requires long-term conservative treatment, including scoliosis-specific therapeutic exercises. The success of exercise-based treatment largely depends on adolescents' motivation to start and continue exercising. However, exercise motivation has not been adequately evaluated in adolescents with idiopathic scoliosis using validated tools specific to this population.

The Behavioral Regulation in Exercise Questionnaire-2 (BREQ-2) is a widely used questionnaire based on Self-Determination Theory that assesses different types of motivation toward exercise. Although the Turkish version of the BREQ-2 exists, its validity and reliability have not yet been examined in adolescents with idiopathic scoliosis.

The purpose of this study is to evaluate the validity and reliability of the Turkish version of the BREQ-2 in adolescents diagnosed with idiopathic scoliosis. Adolescents aged 10-19 years who have been participating in scoliosis-specific therapeutic exercise programs for at least two months will be invited to complete online questionnaires. The results of this study will help determine whether the BREQ-2 is an appropriate tool for assessing exercise motivation in this population and may support the development of individualized motivational strategies in scoliosis rehabilitation.

Eligibility criteria

Qualifiers

Aged between 10 and 19 years

Diagnosed with adolescent idiopathic scoliosis

Receiving scoliosis-specific therapeutic exercise treatment for at least 2 months

Able to read and write in Turkish

Disqualifiers

Presence of congenital or neuromuscular scoliosis

Presence of systemic disease

Presence of syndromic conditions such as Marfan syndrome or Ehlers-Danlos syndrome

Trial design

Treatments tested in this trial

  • Questionnaire Assessment

Treatment groups

95 Participants
are divided into 1 treatment group